Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by the rearrangement of extracellular matrix and progressive increase in the amount of fibrotic tissue in the lung. IGF-I is a potent profibrogenic molecule and its bioavailability is dependent on at least 6 binding proteins called IGFBPs. Among these, IGFBP-3 is the most represented in serum and in different connective tissues. The purpose of this study was to identify and characterize IGFBP-3 in bronchoalveolar lavage (BAL) fluids. We studied 11 patients with IPF and 6 normal subjects by performing baseline pulmonary function test and BAL. IGF-I and IGFBP-3 were measured by RIA in BAL and serum. No significant differences were observed between serum IGF-I and IGFBP-3 from IPF patients and normal subjects. Instead, the direct measurement in BAL revealed a significant increase of IGF-I and IGFBP-3 in IPF patients compared to normal subjects. BAL IGF-I and IGFBP-3 concentrations were significantly related to inspiratory vital capacity (IVC) and carbon dioxide partial pressure (PaCO2): the higher the value of IVC and the lower the value of PaCO2, the higher the level of IGF-I and IGFBP-3. In conclusion, IGFBP3 and IGF-I could be important local mediators of IPF. Their direct measurement in BAL in IPF patients could be used as a clinical marker of the disease, since high levels of IGFBP-3 and IGF-I in BAL are associated to the initial phase of the disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16: 3–34.
Rechler M.M. Insulin-like growth factor binding proteins. Vitam. Horm. 1993, 47: 1–114.
Shimasaki S., Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, -6). Progr. Growth Factor Res. 1991, 3: 243–266.
Kim H.S., Nagalla S.R, OH Y., Wilson E., Roberts C.T. Jr., Rosenfeld R.G. Identification of a family of low affinity insulin-like growth factor binding proteins (IGFBPs), characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc. Natl. Acad. Sci. USA 1997, 94: 12981–12986.
Baxter R.C. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J. Clin. Endocrinol. Metab. 1988, 67: 265–272.
Clemmons D.R. Insulin-like growth factor binding proteins control secretion and mechanism of action. Adv. Exp. Med. Biol. 1991, 293: 113–123.
Giannini S., Maggi M., Cresci B., Fusetti G., Bonaccorsi L., Luconi M., Rotella C.M., Forti G., Serio M., Baldi E. Platelet activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line. Gynecol. Oncol. 1996, 61: 333–340.
Giannini S., Mohan S., Kasuya J., Galli G., Rotella C.M., Le Bon T.R., Fujita-Yamaguchi Y. Characterization of insulin-like growth factor binding proteins produced by cultured fibroblasts from patients with non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus or obesity. J. Clin. Endocrinol. Metab. 1994, 79: 1824–1830.
Giannini S., Cresci B., Manuelli C., Fujita-Yamaguchi Y., Romagnani P., Mohan S., Rotella C.M. Insulin-like growth factor binding protein production in bovine retinal cells. Metabolism 1997, 46: 1367–1379.
Mc-Cusker R.H., Busby W.H., Dehof M.H., Camacho-Hubner C., Clemmons D.R. Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGFbinding proteins. Endocrinology 1991, 129: 2631–2638.
Giudice L.C., Farrel E.M., Pham H., Lamson G., Rosenfeld R.G. Insulin-like growth factor binding proteins in the maternal serum throughout gestation and in the puerperium: effects of pregnancy-associated serum protease activity. J. Clin. Endocrinol. Metab. 1990, 71: 806–816.
Davenport M.L., Isley W.L., Pucilowska J.B., Pemberton L.B., Lyman S., Underwood L.E., Clemmons D.R. Insulin-like growth factor binding protein-3 proteolysis is induced after elective surgery. J. Clin. Endocrinol. Metab. 1992, 75: 590–595.
Oh Y., Muller H.L., Lamson G., Rosenfeld R.G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J. Biol. Chem. 1993, 268: 14964–14971.
Pugliese G., Pricci F., Locuratolo N., Romano G., Giannini S., Cresci B., Rotella C.M., Di Mario U. Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions. Relation to glucose-enhanced extracellular matrix production. Diabetologia 1996, 39: 775–784.
Pugliese G., Pricci F., Romeo G., Pugliese F., Menè P., Giannini S., Galli G., Rotella C.M., Vlassara H., Di Mario U. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997, 46: 1881–1887.
Vanhee D., Gosset P., Wallaert B., Voisin C., Tonnel A.B. Mechanism of fibrosis in coal workers’ pneumoconiosis. Increased production of platelet-derived growth factor, insulin-like growth factor type I, and transforming growth factor-β and relationship to disease severity. Am. J. Respir. Crit. Care Med. 1994, 150: 1049–1055.
Allen J.T., Bloor C.A., Knight R.A., Spiteri M.A. Expression of insulin-like growth factor binding proteins in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Am. J. Respir. Cell. Mol. Biol. 1998, 19: 250–258.
Harrison N.K., Cambrey A.D., Myers A.R., Southcott A.M., Black C.M., du Bois R.M., Lautent G.J., McAnult R.J. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin. Sci. (Calch.) 1994, 86: 141–148.
Aston C., Jagirdar J., Lee T.C., Hur T., Hintz R.L., Rom W.N. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995, 151: 1597–1603.
Allen J.T., Knight R.A., Bloor C.A., Spiteri M.A. Enhanced insulin-like growth factor binding proteinrelated protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Cell. Mol. Biol. 1999, 21: 693–700.
Scano G., Garcia Herreros P., Stendardi L., Degre S., De Coster A., Sergysels R. Cardiopulmonary adaptation to exercise in coal miners. Arch. Environ. Health 1990, 35: 360–366.
European Community for Coal and Steel. Standardization of lung function tests. Eur. Respir. J. 1990, 6: 1–100.
Bradford M.M. A rapid and sensitive method for quantitation of micrograms quantities of protein, utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 58: 541–548.
Hosselopp P., Seurin D., Segovia-Quinson B., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins and competitive binding studies. Anal. Biochem. 1986, 154: 138–143.
Mohan S., Jennings J.C., Linkhard T.A., Baylink D.J. Primary structure of human skeletal growth factor: homology with human insulin-like growth factor II. Biochem. Biophys. Acta 1988, 966: 44–55.
Leary J.J., Brigati D.J., Ward D.C. Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: bio-blots. Proc. Natl. Acad. Sci. USA 1983, 80: 4045–4049.
Nakao Y., Hilliker S., Baylink D.J., Mohan S. Studies on the regulation of IGFBP-3 secretion in human osteosarcoma cells in vitro. J. Bone Miner. Res. 1994, 9: 865–872.
Baxter R.C., Martin J.L. Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J. Clin. Invest. 1986, 78: 1504–1512.
Clemmons D.R., Van Wyk J.J., Ridjway E.C., Kilman B., Kjellberg R.N., Underwood L.E. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 1979, 301: 1138–1143.
Pugliese G., Pricci F., Locuratolo N., Romeo G., Romano G., Giannini S., Cresci B., Galli G., Rotella C.M., Di Mario U. Increased activity of Insulin-like growth factor system in mesangial cells cultured in high glucose condition. Relation to glucose-enhanced extracellular matrix production. Diabetologia 1996, 39: 775–784.
Fukuda Y., Ferrans V.J., Schoenberger C.I., Rennard S.I., Crystal R.G. Patterns of pulmonary structural remodeling after experimental paraquat toxicity: the morphogenesis of intralveolar fibrosis. Am. J. Pathol. 1986, 118: 452–475.
Katzenstein A.A., Myers J.L. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. State of the art. Am. J. Respir. Crit. Care Med. 1998, 157: 1301–1315.
Homma S., Nagaoka I., Abe H., Takahashi K., Seyama K., Nukiwa T., Kira S. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am. J. Respir. Crit. Care Med. 1995, 152: 2084–2089.
Kelley J. Cytokines of the lung. Am. Rev. Respir. Dis. 1990, 141: 765–788.
Harrison N.K., Cambrey A.D., Myers A.R., Southcott A.M., Black C.M., du Bois R.M., Laurent G.J., McAnulty R.J. Insulin like growth factor I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin. Sci. (Calch.) 1994, 86: 141–148.
Rom W.N., Paakko P. Activated alveolar macrophages express the insulinlike growth factor-I receptor. Am. J. Respir. Cell. Mol. Biol. 1991, 4: 432–439.
Blum W.F., Ranke M.B., Kietzmann K., Gauggel E., Zeisel H.J., Bierich J.R. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J. Clin. Endocrinol. Metab. 1990, 70: 1292–1298.
Moser D.R., Lowe W.L. Jr., Dake B.L., Booth B.A., Boes M., Clemmons D.R., Bar R.S. Endothelial cells express insulin-like growth factorbinding proteins 2 to 6. Mol. Endocrinol. 1992, 6: 1805–1814.
Maeda A., Hiyama K., Yamakido H., Ishioka S., Yamakido M. Increased expression of platelet-derived growth factor A and insulin-like growth factor I in BAL. Cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 1996, 109: 780–786.
Rajaram S., Baylink D.J., Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr. Rev. 1997, 18: 801–831.
Tucci M., Nyagard K., Tanswell B.V., Farber H.W., Hill D.J., Han V.K. Modulation of insulin-like growth factor (IGF) and IGF protein biosynthesis by hypoxia in cultured vascular endothelial cells. J. Endocrinol. 1998, 157: 13–24.
Blat C., Villaudy J., Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. Clin. Invest. 1994, 93: 2286–2290
Bach L.A., Rechler M.M. Insulin-like growth factor binding proteins. Diabetes Rev. 1995, 3: 38–61.
Keogh B.A., Crystal R.G. Pulmonary function testing in interstitial pulmonary disease. Chest 1980, 78: 856–865.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pala, L., Giannini, S., Rosi, E. et al. Direct measurement of IGF-I and IGFBP-3 in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis. J Endocrinol Invest 24, 856–864 (2001). https://doi.org/10.1007/BF03343942
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343942